bluebird bio Q4 EPS Estimate Increased by Leerink Partnrs

bluebird bio, Inc. (NASDAQ:BLUEFree Report) – Research analysts at Leerink Partnrs upped their Q4 2024 earnings estimates for shares of bluebird bio in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($4.42) per share for the quarter, up from their prior estimate of ($4.47). The consensus estimate for bluebird bio’s current full-year earnings is ($27.17) per share. Leerink Partnrs also issued estimates for bluebird bio’s FY2025 earnings at ($6.42) EPS.

Several other equities research analysts have also recently commented on BLUE. StockNews.com initiated coverage on bluebird bio in a research note on Friday, December 20th. They set a “sell” rating for the company. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $60.00 to $10.00 in a research report on Friday, November 15th. JPMorgan Chase & Co. downgraded shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Barclays raised their price target on shares of bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, December 31st. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $80.00 price objective on shares of bluebird bio in a report on Friday, November 15th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $49.14.

View Our Latest Research Report on BLUE

bluebird bio Stock Performance

BLUE stock opened at $7.80 on Friday. The firm has a market cap of $75.82 million, a PE ratio of -0.21 and a beta of 0.68. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The stock has a 50-day moving average price of $8.17 and a 200-day moving average price of $11.81. bluebird bio has a 1-year low of $5.80 and a 1-year high of $38.40.

Hedge Funds Weigh In On bluebird bio

Several large investors have recently added to or reduced their stakes in BLUE. Verition Fund Management LLC bought a new position in shares of bluebird bio during the third quarter valued at about $42,000. SG Americas Securities LLC lifted its position in shares of bluebird bio by 152.4% during the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after buying an additional 74,185 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after buying an additional 77,293 shares in the last quarter. Barclays PLC boosted its stake in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after buying an additional 184,605 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 355,562 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

(Get Free Report)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Featured Articles

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.